Cardinal Health Company Profile (NYSE:CAH)

Cardinal Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "CAH."

Cardinal Health declared a quarterly dividend on Wednesday, May 3rd. Shareholders of record on Monday, July 3rd will be given a dividend of $0.4624 per share on Saturday, July 15th. This represents a $1.85 dividend on an annualized basis and a yield of 2.41%. The ex-dividend date is Thursday, June 29th. This is a boost from Cardinal Health's previous quarterly dividend of $0.45. View Cardinal Health's Dividend History.

Cardinal Health, Inc. (NYSE:CAH) issued its quarterly earnings data on Monday, May, 1st. The company reported $1.53 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.46 by $0.07. The company had revenue of $31.82 billion for the quarter, compared to analyst estimates of $32.30 billion. Cardinal Health had a return on equity of 25.78% and a net margin of 1.05%. The business's quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the business earned $1.43 earnings per share. View Cardinal Health's Earnings History.

Cardinal Health is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for Cardinal Health.

17 brokerages have issued 12-month price objectives for Cardinal Health's stock. Their forecasts range from $72.00 to $93.00. On average, they anticipate Cardinal Health's stock price to reach $83.46 in the next year. View Analyst Ratings for Cardinal Health.

Here are some recent quotes from research analysts about Cardinal Health stock:

• 1. According to Zacks Investment Research, "Cardinal Health ended third-quarter fiscal 2017 on a solid note, courtesy of encouraging performance in the Medical segment. However, revenues missed the estimate mark in the quarter. Profits at the Pharmaceutical segment were hurt by generic pharmaceutical pricing and the loss of a major Pharmaceutical Distribution customer. Over the past one year, the company has underperformed the broader industry with respect to price. Increasing generic pricing pressure is a major headwind at the moment. Moreover, intensifying competition and customer concentration are other bottlenecks. Sluggish macroeconomic situations and a tough product pricing environment are also likely to dent growth. The company is banking on strategic buyouts, joint ventures and supply agreements to drive growth. Despite the strong prospects, integration risks are likely to mar the company's bottom line in the near term." (7/4/2017)
• 2. Leerink Swann analysts commented, "We were disappointed by the pharmaceutical operating margin of 1.92% (-24 bps y/y) which was below our 2.02%E, though operating income itself was ahead of our estimate. The Medical division revenue was slightly ahead of our model, and operating income of $122M (margin of 3.80% vs. 4.49%E) was roughly in-line. Cordis is seasonal in nature and as a result earnings were good in Medical last quarter. F2017 Outlook Tough but Long-term +10-15% EPS Growth Guidance Good. Management provided F2017 guidance of $5.48-$5.73. The midpoint of guidance of $5.61 is below consensus of $5.69 and CAH indicated that F1Q:17 pharma operating income would decline in the ‘high teens to low twenty percent range,’ though be flat for F2017 relative to F2016. While this would normally be highly worrisome, management did a good job explaining that F1Q:16 EPS grew +38% y/y and the comp. is difficult due largely to generic pricing trends. In CAH’s prepared presentation, and on the call, management highlighted that they ‘aspire’ to grow adjusted EPS by +10-15% y/y over the longer term. Net customer activity and pricing is expected to have a ($0.55) headwind on F2017 results, tied mainly to Safeway, generic deflation, and less incremental earnings from new generic launches and Red Oak." (8/3/2016)

Cardinal Health saw a drop in short interest during the month of July. As of July 14th, there was short interest totalling 7,957,121 shares, a drop of 24.2% from the June 30th total of 10,498,346 shares. Based on an average trading volume of 1,287,718 shares, the days-to-cover ratio is presently 6.2 days. Currently, 2.5% of the shares of the stock are sold short.

Some companies that are related to Cardinal Health include Becton, Dickinson and Company (BDX), Takeda Pharmaceutical (TKPYY), Vertex Pharmaceuticals Incorporated (VRTX), Boston Scientific Corporation (BSX), Express Scripts Holding Company (ESRX), Intuitive Surgical (ISRG), McKesson Corporation (MCK), Humana (HUM), Teva Pharmaceutical Industries Limited (TEVA), Baxter International (BAX), Zoetis (ZTS), Alexion Pharmaceuticals (ALXN), HCA Holdings (HCA), Actelion (ALIOF), Fresenius Medical Care Corporation (FMS), Incyte Corporation (INCY), Grifols, S.A. (GRFS) and Illumina (ILMN).

Cardinal Health's management team includes the folowing people:

• George S. Barrett, Chairman of the Board, Chief Executive Officer
• Michael C. Kaufmann, Chief Financial Officer
• Donald M. Casey Jr., Chief Executive Officer - Medical Segment
• Jon L. Giacomin, Chief Executive Officer - Pharmaceutical segment
• Pamela O. Kimmet, Chief Human Resource Officer
• Patricia B. Morrison, Executive Vice President - Customer Support Services and Chief Information Officer
• Craig S. Morford, Chief Legal and Compliance Officer
• Gregory B. Kenny, Lead Independent Director
• David John Anderson, Independent Director
• Colleen F. Arnold, Independent Director

Cardinal Health's stock is owned by a number of of institutional and retail investors. Top institutional investors include APG Asset Management N.V. (0.46%), Hexavest Inc. (0.31%), Russell Investments Group Ltd. (0.28%), PGGM Investments (0.28%), Bank of Montreal Can (0.22%) and Great West Life Assurance Co. Can (0.14%). Company insiders that own Cardinal Health stock include Carole S Watkins, Craig S Morford, Donald M Jr Casey, Falk T Stephen, George S Barrett, Jon L Giacomin, Patricia Morrison and Stuart G Laws. View Institutional Ownership Trends for Cardinal Health.

Cardinal Health's stock was sold by a variety of institutional investors in the last quarter, including US Bancorp DE, Acadian Asset Management LLC, Great West Life Assurance Co. Can, Eastern Bank, Russell Investments Group Ltd., Reinhart Partners Inc., Hexavest Inc. and Whittier Trust Co.. Company insiders that have sold Cardinal Health stock in the last year include Craig S Morford, Donald M Jr Casey, George S Barrett, Jon L Giacomin, Patricia Morrison and Stuart G Laws. View Insider Buying and Selling for Cardinal Health.

Cardinal Health's stock was bought by a variety of institutional investors in the last quarter, including Harbour Capital Advisors LLC, Strs Ohio, Bank of Montreal Can, Manning & Napier Advisors LLC, Boston Advisors LLC, Mn Services Vermogensbeheer B.V., Wealth Enhancement Advisory Services LLC and National Pension Service. View Insider Buying and Selling for Cardinal Health.

Shares of Cardinal Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Cardinal Health stock can currently be purchased for approximately $76.60.